SecBot SecBot
8-K ·Filed Jun 22, 2026

RVMD

Revolution Medicines, Inc.
NEUTRAL
Impact 2/10
Horizonmonths Processed4mo ago SEC0001193125-26-276718
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

The planned retirement is orderly with a six-month transition period and potential board retention, reducing immediate leadership risk. Monitor for any successor appointment for the President of R&D role and for the Board's decision on Dr. Kelsey's directorship. No trading catalyst from this filing.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$165.81
T+0 close · Jun 22, 2026 · via day close
Latest settled
+23.55%
T+60 · $204.86
Vs SPY
+21.80%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 22 $165.81entry
  2. T+1 · 5mo ago +2.23%α +3.68% · $169.51
  3. T+5 · 5mo ago +16.17%α +16.62% · $192.62
  4. T+20 · 4mo ago +12.27%α +12.42% · $186.16
  5. T+60 · 2mo ago +23.55%α +21.80% · $204.86
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Revolution Medicines filed an 8-K announcing the planned retirement of President of R&D Steve Kelsey, effective January 4, 2027, with a transition to senior advisor starting July 1, 2026, and a contemplated board appointment. The filing also reports routine annual meeting results, including the election of two Class III directors and ratification of the auditor. No financial data or material business changes were disclosed.

Key Facts

  • Steve Kelsey, M.D., President of Research and Development, intends to retire effective January 4, 2027.
  • Dr. Kelsey will transition to Senior Advisor to the CEO from July 1, 2026, until retirement.
  • The company contemplates appointing Dr. Kelsey to the Board of Directors upon his retirement, subject to Board approval.
  • Annual meeting results: Alexis Borisy and Mark A. Goldsmith elected as Class III directors; PwC ratified as auditor; advisory say-on-pay approved.

Financial Impact

No financial impact from this filing.

Risk Factors

  • Potential loss of key R&D leadership if transition does not proceed as planned.
  • Successor not yet named, creating uncertainty in R&D pipeline execution.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
96% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-276718
Document: 0001193125-26-276718-index-headers.html0001193125-26-276718
Document: 0001193125-26-276718-index.html0001193125-26-276718
Document: 0001193125-26-276718.txt0001193125-26-276718

US Market Status

Market Closed · Opens in 8h 44m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026